Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (925)	12/8/2005 12:51:45 AM
From: richardred	Read Replies (2) \| Respond to of 7256

>IVGN Our Business and Operating Segments We are a leading developer, manufacturer and marketer of research tools in reagent, kit and high throughput application forms to customers engaged in life sciences research, drug discovery, diagnostics and the commercial manufacture of biological products. Additionally we are a leading supplier of sera, cell and tissue culture media and reagents used in life sciences research, as well as in processes to grow cells in the laboratory and produce pharmaceuticals and other high valued proteins. We conduct our business through two principal segments: † BioDiscovery. Our BioDiscovery product segment includes our functional genomics, cell biology and drug discovery product lines. Functional genomics encompasses products from the initial cloning and manipulation of DNA, to examining RNA levels and regulating gene expression in cells, to capturing, separating and analyzing proteins. These include the research tools used in reagent and kit form that simplify and improve gene acquisition, gene cloning, gene expression, and gene analysis techniques. This segment also includes a full range of enzymes, nucleic acids, other biochemicals and reagents. These biologics are manufactured to the highest research standards and are matched in a gene specific, validated manner (gene, orf, rnai, protein, antibodies, etc.) to ensure researchers the highest purity and scientific relevance for their experimentation. We also offer software through this segment that enables more efficient, accelerated analysis and interpretation of genomic, proteomic and other biomolecular data for application in pharmaceutical, therapeutic and diagnostic development. The recent acquisitions of Zymed and Dynal have introduced and will continue to enable us to offer new technology and products, such as antibodies and proteins (Zymed) and magnetic beads used for biological separation (Dynal), which is the first step in almost every biologic investigative or diagnostic process. biz.yahoo.com

To: richardred who wrote (925)	12/8/2005 12:48:49 PM
From: richardred	Respond to of 7256

An added plus A GE tie now! Invitrogen President Elected to California Healthcare Institute Board Thursday December 8, 12:19 pm ET LA JOLLA, Calif.--(BUSINESS WIRE)--Dec. 8, 2005--Benjamin E. Bulkley, president, Commercial Operations, Invitrogen Corporation (Nasdaq:IVGN - News), was elected to the board of directors of California Healthcare Institute (CHI). CHI is a non-profit public policy research organization representing leading California academic institutions, biotechnology, medical device, and pharmaceutical firms. Source: California Healthcare Institute · Benjamin Bulkley, Invitrogen, elected to CHI Board (Photo: Business Wire). View Multimedia Gallery Bulkley joined Invitrogen in October of 2003. For the 16 years prior, he worked at General Electric (GE) in various leadership roles across the organization, most recently vice president of global services for GE's Medical Systems Information Technologies division where he was responsible for a 1,500-person global service business, including marketing and sales, customer training, call centers, and parts/supplies distribution. While with GE, Bulkley also helped develop best practices for acquisition integrations. He received his B.S. in Electrical Engineering from the University of Connecticut, and M.S. in Systems Engineering from Gannon University in Pennsylvania. "With Invitrogen's central role in California's biomedical research and development community, Ben is well positioned to help advance our mission of advocating positive public policy for life sciences companies and universities," said David Gollaher, Ph.D., CHI president and CEO. CHI represents more than 250 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI's mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI's web site is www.chi.org. Invitrogen Corporation, headquartered in Carlsbad, Calif., provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's research and development efforts are focused on breakthrough innovation in all major areas of biological discovery, including functional genomics, proteomics, bioinformatics, and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. For more information, visit www.invitrogen.com. MULTIMEDIA AVAILABLE: businesswire.com Contact: California Healthcare Institute Molly Ingraham, 858-551-6677 ingraham@chi.org Source: California Healthcare Institute biz.yahoo.com

To: richardred who wrote (925)	3/1/2006 2:01:12 PM
From: richardred	Respond to of 7256

Good news on IVGN today!

To: richardred who wrote (925)	1/30/2007 12:20:37 AM
From: richardred	Respond to of 7256

MDS to acquire Molecular Devices for $615M Monday January 29, 4:37 pm ET MDS Inc. said Monday it will acquire Molecular Devices Corp. for $615 million in cash. Toronto-based MDS (NYSE:MDZ - News) said the deal values Sunnyvale-based Molecular Devices' (NASDAQ:MDCC - News) common shares at $35.50 each, about a 49 percent premium compared to Friday's close at $23.88. MDS said the combined company will have more than 1,100 employees. The agreement has been unanimously approved by the boards of both companies. MDS will commence a cash tender offer for all of the outstanding shares of Molecular Devices. MDS said it will create a new business unit that will combine the Molecular Devices and MDS Sciex businesses. It will be led by the current president of MDS Sciex, Andy Boorn. Merrill Lynch & Co. is acting as exclusive financial advisor to MDS; Ropes & Gray LLP is acting as legal counsel to MDS in this transaction. UBS Investment Bank is acting as exclusive financial advisor to Molecular Devices; Cooley Godward Kronish LLP is acting as legal counsel to Molecular Devices. Published January 29, 2007 by the Silicon Valley / San Jose Business Journal biz.yahoo.com

To: richardred who wrote (925)	4/13/2007 1:28:48 AM
From: richardred	Respond to of 7256

Invitrogen Completes Divestiture of BioReliance Thursday April 12, 4:00 pm ET CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (Nasdaq:IVGN - News), a provider of essential life science technologies for disease research and drug discovery, today announced it has completed the sale of its BioReliance business unit to Avista Capital Partners for $210 million. "The decision to sell BioReliance followed a thorough portfolio review aimed at identifying our core competencies," said Greg Lucier, Chairman and Chief Executive Officer of Invitrogen. "This divestiture allows us to focus on our core platform of tools and technologies and to grow our position as the premier consumables company in the marketplace." BioReliance is a contract service organization that provides biological safety, testing, toxicology, viral manufacturing and laboratory animal diagnostic services. About Invitrogen Invitrogen Corporation (Nasdaq:IVGN - News) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company is celebrating 20 years of accelerating scientific discovery. Invitrogen globally employs approximately 4,300 scientists and other professionals and had revenues of more than $1.26 billion in 2006. For more information, visit www.invitrogen.com. About Avista Capital Partners Avista Capital Partners is a leading private equity firm with offices in New York, NY and Houston, TX. Founded in 2005, Avista's strategy is to make controlling or influential minority investments primarily in growth-oriented media, healthcare and energy companies. Through its team of seasoned investment professionals and industry experts, Avista seeks to partner with exceptional management teams to invest in and add value to well-positioned businesses. For more information, visit www.avistacap.com. Contact: Invitrogen Corporation Investor Relations Amanda Clardy, 760-603-7200 amanda.clardy@invitrogen.com Media Contact Eric Endicott, 760-268-7438 eric.endicott@invitrogen.com Source: Invitrogen Corporation biz.yahoo.com